S-1/A: Picard Medical Files S-1/A for Resale of 17M Shares

Picard Medical, Inc. filed an S-1/A registration statement for the resale of up to 17,000,000 shares of common stock by selling stockholders, including shares from senior secured notes and warrants, with no direct proceeds to the company from these sales.

Summary

• Picard Medical, Inc. (PMI) filed an S-1/A registration statement for the resale of up to 17,000,000 shares of common stock by HT Investments MA LLC and High Trail Special Situations LLC (Selling Stockholders).
• The shares include 7,009,346 shares issuable upon exercise of warrants (initial exercise price $2.675 per share) and 9,990,654 shares issuable upon conversion, redemption, or settlement of senior secured notes due December 24, 2028.
• PMI will not receive any proceeds from the sale of these shares by the Selling Stockholders, but may receive proceeds from any cash exercise of the warrants, which will be used for general corporate purposes.
• The company has a history of significant net losses: $21.1 million for the year ended December 31, 2024, $15.6 million for the year ended December 31, 2023, $22.7 million for the nine months ended September 30, 2025, and $12.2 million for the nine months ended September 30, 2024.
• As of September 30, 2025, the accumulated deficit was $72.6 million, and the independent auditor's report for 2024 included an explanatory paragraph regarding the company's ability to continue as a going concern.
• Total revenues decreased by 13% to $4.391 million for the year ended December 31, 2024, compared to $5.043 million in 2023, primarily due to a decline in U.S. and foreign product sales.
• For the nine months ended September 30, 2025, total revenues increased by 11% to $3.931 million, compared to $3.555 million in the same period of 2024, driven by increased U.S. product sales offset by decreases in Europe and the rest of the world.
• Gross loss was $112,000 for the year ended December 31, 2024, compared to $2.311 million in 2023, and $615,000 for the nine months ended September 30, 2025, compared to $248,000 in the same period of 2024.
• Research and development expenses increased by 53% to $3.380 million in 2024, but decreased by 3% to $2.502 million for the nine months ended September 30, 2025.
• Selling, general and administrative expenses decreased by 7% to $10.220 million in 2024, and decreased by 2% to $7.137 million for the nine months ended September 30, 2025.
• Total other expenses significantly increased by 10,564% to $7.358 million in 2024 and by 498% to $12.426 million for the nine months ended September 30, 2025, primarily due to derivative (non-cash) accounting for convertible notes.
• The company completed its IPO on September 2, 2025, issuing 4,250,000 shares at $4.00 per share, raising $17 million in gross proceeds, and an additional $2.6 million from an over-allotment option.
• The IPO triggered the conversion of $4.135 million of 2023 Convertible Notes, $5.7 million of 2024 Convertible Notes, and $7.0 million of Nexus and Another Dimension notes into 19,634,860 shares of common stock.
• PMI is developing a next-generation, fully implantable total artificial heart called 'Emperor' and expects FDA approval as early as 2028, with initial animal studies completed.
• The company is also developing upgraded portable (Freedom+) and hospital (Companion 3) drivers, with Freedom+ FDA approval anticipated by the second half of 2025 and Companion 3 by the second half of 2027.
• PMI is seeking to expand the SynCardia TAH's Indications for Use (IFU) to include 'bridge to candidacy' (BTC) and 'long-term use' (2 years or more), with an FDA answer on the 180-day PMA supplement expected in Q2 2026.
• In Europe, PMI voluntarily withdrew its CE MDD certificate in 2022 and is working towards CE MDR certification, with submission expected in the second half of 2025.
• PMI has identified a cannula tear issue in the SynCardia TAH, with 104 reports but zero Serious Adverse Events as of March 20, 2025; a design change is being validated for FDA submission in Q3 2025.
• The company has significant customer concentrations, with Customer A accounting for 49% of revenue for the nine months ended September 30, 2025.
• PMI has entered into an Investment Agreement to acquire a 60% ownership interest in SynCardia Medical (Beijing), Inc. for $2.85 million, contingent on PMI becoming publicly traded, to facilitate distribution in China.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the successful IPO and new financing provide much-needed capital and validate market interest, the company's significant and increasing net losses, negative gross margins, and ongoing 'going concern' warning indicate substantial operational challenges and a high-risk profile. The long development timelines for new products and regulatory hurdles for market expansion also temper enthusiasm.

Positives

• Successfully completed an Initial Public Offering (IPO) on September 2, 2025, raising $17 million in gross proceeds, plus an additional $2.6 million from an over-allotment option.
• The IPO and subsequent over-allotment provided significant cash flow, with net cash provided by financing activities at $14.061 million for the nine months ended September 30, 2025.
• Total revenues increased by 11% for the nine months ended September 30, 2025, compared to the same period in 2024, driven by a $0.87 million increase in U.S. product sales.
• Gross loss improved significantly for the year ended December 31, 2024, decreasing by 95% to $112,000 from $2.311 million in 2023.
• The SynCardia TAH is the only implantable total artificial heart approved by the U.S. FDA and Health Canada as a bridge to heart transplantation, with over 2,100 implants in 27 countries.
• Development of 'Emperor,' a next-generation, driver-less, fully implantable STAH, is underway with successful acute pre-clinical animal studies completed, showing stable circulatory support and efficient energy utilization.
• Anticipated FDA approval for the upgraded portable Freedom+ Driver by the second half of 2025, which is expected to be more durable and reduce false alarm rates.
• Progress in seeking expanded Indications for Use (IFU) for the SynCardia TAH to include 'bridge to candidacy' (BTC) and 'long-term use' (2 years or more), with FDA feedback expected in Q2 2026.
• Successful completion of the latest MDSAP audit in November 2024, with no deficiencies noted, indicating strong quality management systems.
• Strong intellectual property coverage for the next-generation total artificial heart, including newly awarded U.S. patents No. 11,918,798 and No. 12,121,711 B2, and China patent CN 115279450 B.
• The company's proprietary Segmented Polyurethane Solution (SPUS) for heart ventricles is FDA approved and has extensive clinical experience, presenting a significant competitive barrier.
• Real-world data (RWD) from the INTERMACS registry shows a relatively low incidence of neurological events (5% of total adverse events) for SynCardia TAH patients, comparing favorably to the PMA FDA study (27%).
• One-year survival rates for SynCardia TAH patients in RWD settings range from 75% to 86.6%, confirming and expanding upon PMA FDA study findings.
• Established international presence with a subsidiary in Germany and a planned majority acquisition of SynCardia Medical (Beijing), Inc. for the Chinese market, and efforts to enter the Indian and Middle Eastern markets.

Negatives

• Significant history of net losses, including $22.7 million for the nine months ended September 30, 2025, and an accumulated deficit of $72.6 million.
• Independent auditor's report includes an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• Total cost of revenues as a percentage of total sales was 116% for the nine months ended September 30, 2025, and 103% for the year ended December 31, 2024, indicating negative gross margins.
• Total other expenses increased dramatically by 498% for the nine months ended September 30, 2025, primarily due to non-cash derivative losses on convertible notes.
• Reliance on a limited number of products (SynCardia TAH and drivers) for substantially all revenue, making the business vulnerable to declines in sales or market acceptance of these products.
• Manufacturing process requires highly specialized knowledge and operator skills, making it difficult to replace personnel quickly and risking production delays.
• Reliance on single-source suppliers for the majority of critical components, including driver components and SynHall Valves, posing significant supply chain risks.
• The future demand for current and future products is unproven, and physicians may be reluctant to adopt the SynCardia TAH due to perceived risks or existing alternatives like LVADs.
• Voluntary withdrawal of CE MDD certificate in Europe in 2022 due to post-market surveillance deficiencies, potentially limiting market access until CE MDR certification is obtained.
• Many aspects of the SynCardia TAH are no longer protected by patents, increasing reliance on trade secrets which are vulnerable to misappropriation or independent development by competitors.
• Outstanding royalty payments of approximately $492,000 to Medtronic as of December 31, 2024, with Medtronic holding a first-priority security interest in the license, posing a risk of foreclosure or litigation.
• The company may not have access to the full $35 million additional financing under the Purchase Agreement, as subsequent draws require the Selling Stockholders' consent and satisfaction of conditions.
• The notes and warrants include a 9.99% beneficial ownership limitation and stock exchange caps on share issuances until stockholder approval is obtained, potentially constraining future equity-linked financings.
• The Purchase Agreement imposes restrictions on alternative equity-linked financing while notes are outstanding, limiting flexibility to raise capital.
• The company has not declared or paid cash dividends and does not intend to in the foreseeable future, which may not appeal to certain investors.

Risks

• History of significant losses and inability to achieve and sustain profitability, leading to potential financial distress.
• All revenue generated from a limited number of products, making the business vulnerable to declines in sales or market acceptance.
• Manufacturing process requires highly specialized knowledge and operator skills, risking production delays and quality issues.
• Reliance on specialized single-source suppliers for critical components, including driver components and SynHall Valves, without readily available second sources.
• Unproven future demand for current and future products, with potential reluctance from hospitals, surgeons, or patients to adopt.
• Inability to educate physicians on the safe and effective use of the SynCardia TAH and its implantation procedure, hindering growth.
• Failure to develop and retain a direct sales force and effective network of international distributors, impacting growth targets.
• Reliance on distributors and third parties to market and sell products, with risks of unsuitable partners, premature terminations, or unfavorable terms.
• Operating in a market segment subject to rapid technological change, with competitors potentially developing superior products.
• Significant customer concentrations, leading to revenue fluctuations due to changes in economic conditions or purchasing policies of key customers.
• Inability to develop, receive regulatory approval for, and timely introduce new products or product enhancements, impacting competitiveness.
• Premarket approvals for therapeutic medical devices could be denied or significantly delayed due to lengthy, costly, and uncertain regulatory processes.
• Extensive post-marketing regulation by the FDA and comparable authorities, leading to significant compliance costs and potential enforcement actions.
• Inadequate coverage and reimbursement from third-party payors (U.S. and international) for product use, negatively impacting revenues.
• Manufacturing operations, R&D, and corporate headquarters based at a single location, exposing the company to risks from disasters or disruptions.
• Product liability claims, product recalls, or product misuse could damage reputation, incur substantial costs, and lead to litigation.
• Claims related to improper handling, storage, or disposal of hazardous chemicals and biomaterials, leading to costly legal and regulatory issues.
• International operations subject to operating risks, including difficulties in enforcing IP rights, pricing pressure, political instability, and trade policy changes.
• Credit risk from accounts receivable, especially from foreign customers in economically unstable regions.
• Risks associated with currency fluctuations, impacting results of operations and distorting period-to-period comparisons.
• Changes in U.S. and foreign tax laws, including the Tax Cuts and Jobs Act, CARES Act, and Inflation Reduction Act, could materially affect financial condition.
• Ability to use net operating loss carryforwards and other tax attributes may be subject to limitations due to ownership changes.
• Inaccuracy of industry and market-related estimates, potentially leading to overestimating market opportunity.
• Inability to attract and retain highly qualified personnel due to intense competition in the medical device industry.
• Risks associated with future acquisitions, including failure to achieve anticipated revenues/synergies, integration difficulties, and dilution.
• Failure to protect information technology infrastructure against cyber-based attacks, network security breaches, or data corruption.
• Cybersecurity risks associated with using medical devices, potentially endangering patient safety and marketability.
• Demand for total artificial hearts depends on factors like medical advances that could provide better alternatives or replace SynCardia TAHs.
• Extensive governmental regulation making it expensive and time-consuming to introduce new or improved products.
• Off-label use or misuse of products could harm market image, lead to product liability suits, and regulatory sanctions.
• Non-compliance with medical device reporting (MDR) requirements, leading to corrective actions or enforcement.
• Misconduct by employees, contractors, or partners, including non-compliance with regulatory standards and healthcare fraud laws.
• Failure to obtain approval for long-term indications (2 years or more) for the SynCardia TAH within the next year, requiring additional clinical trials.
• Failure to reinstate CE certificate under CE MDR in Europe, limiting ability to market or sell products in European markets.
• Prior weaknesses in CE MDD regulatory regime and compliance with EU medical device regulations, limiting market access.
• Many aspects of the SynCardia TAH no longer protected by patents, making it difficult to protect from competition.
• Extensive patent and intellectual property litigation in the medical device industry, leading to costly disputes, diversion of management attention, or significant damages.
• Cessation of commercial ties with Bimba or Heitek Automation, sole source suppliers for crucial driver components, could negatively impact business.
• Claims of inadvertent or intentional use/disclosure of trade secrets or proprietary information of former employers by employees.
• Share price volatility and potential for substantial losses for purchasers of securities.
• Incurring increased costs and demands upon management due to complying with laws and regulations affecting public companies.
• Inability to implement and maintain effective internal control over financial reporting, leading to loss of investor confidence.
• Lack of research or inaccurate/unfavorable research from securities or industry analysts, causing stock price decline.
• Charter designates specific courts as exclusive forum for stockholder litigation, potentially limiting stockholders' ability to obtain a favorable forum.
• Resale of shares by Selling Stockholders, including those from convertible notes and warrants, may depress market price and dilute existing stockholders.
• Unpredictable number of shares sold to Selling Stockholders or gross proceeds from sales.
• Management's broad discretion over use of proceeds, which may not align with investor expectations or be invested successfully.
• Limited access to the full amount available under the Purchase Agreement due to conditions and Selling Stockholders' consent.
• Restrictions in the Purchase Agreement limiting alternative equity-linked financing while notes are outstanding.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it expands sales and marketing, increases manufacturing, pursues additional regulatory approvals, and continues R&D activities. Key priorities include developing the next-generation 'Emperor' fully implantable STAH (expected FDA approval as early as 2028), next-generation portable and hospital drivers (expected FDA approvals in late 2026 and 2027 respectively), and expanding sales and channel presence in existing and new geographies. The company plans to seek FDA approval for long-term indications (2 years or more) for the SynCardia TAH, with an answer on the PMA supplement expected in Q2 2026. Efforts are also underway to obtain CE MDR certification in Europe by the second half of 2025 and NMPA approval in China within 12 months from filing.

Management Comments

• "Our strategy, consistent with our prior filing, is to advance product innovation, expand our commercial reach and deepen customer engagement while driving scale and operating leverage."
• "Key priorities include developing a next generation, driver-less and fully implantable version of the STAH referred to as Emperor, next-generation portable and hospital drivers, continuing surgeon and center training to support safe adoption to expand our sales and channel presence in existing and new geographies."
• "We believe our installed base, clinical experience and distribution partnerships position us to capture a growing share of the advanced heart failure market."
• "We believe that based on our technology, intellectual property, know-how, and extensive human clinical experience, we have significant advantages over other companies developing other TAH products."
• "We believe that the present and projected demand for SynCardia TAHs depends on a variety of factors. These factors include, but are not limited to, (i) a rising trend in heart related disorders and failures, (ii) a market need for both a short-term and long-term alternative to heart transplants, (iii) industry competition within the total artificial heart space, and (iv) medical advances that could provide permanent solutions to the heart related problems currently addressed by total artificial hearts."
• "We intend to aggressively protect, defend, and extend the intellectual property rights protecting our technology."
• "We consider our relationship with our employees to be good."
• "As a sci-fi fan, [Richard Fang] believes in the ironman heart and has a vision that the SynCardia TAH will be a preferred alternative to heart transplant."

Industry Context

StockSavvy.ai notes that Picard Medical operates in the highly specialized and competitive medical device industry, specifically within advanced heart failure treatment. The company's SynCardia TAH is currently the only FDA and Health Canada approved total artificial heart for bridge to transplant, giving it a unique market position. However, it faces competition from LVADs (e.g., Abbott HeartMate 3) which are more commonly used, and emerging TAH competitors like Carmat (Aeson device, CE mark in EU, but facing insolvency and software issues) and BiVACOR (early-stage human clinical testing). The market is characterized by rapid technological change and extensive regulatory hurdles, requiring continuous innovation and significant R&D investment. The global demand for heart implants is substantial, with significant opportunities outside the U.S., but also presents challenges related to diverse regulatory frameworks and reimbursement policies.

Comparison to Industry Standards

• The SynCardia TAH is the only total artificial heart approved for commercial use in the United States and Canada for bridge to transplant (BTT) indication, providing a significant competitive advantage over other TAH manufacturers.
• Carmat's Aeson device obtained CE mark in Europe in December 2020 under MDD but is currently undergoing re-certification under MDR and has faced quality and software issues, leading to a recommendation for early natural heart transplantation and a filing for insolvency in July 2025. This contrasts sharply with SynCardia's established regulatory approvals and clinical experience.
• BiVACOR's total artificial heart is in early-stage human clinical testing (5 of 20 patients in EFS in the U.S., one patient in Australia) and has not obtained approval for any market, positioning SynCardia significantly ahead in commercialization.
• SynCardia TAH offers 50cc and 70cc ventricle blood volumes, serving men, women, and children, with a total implant size of 250-400ml and weight of 250g. Carmat's Aeson has a 65cc displacement pump, 750ml total implant size, and 900g weight, potentially limiting fit for smaller patients. BiVACOR's 400ml implant size and 650g weight also suggest potential fit limitations.
• SynCardia boasts over 2,100 implants as of July 2025, demonstrating extensive human clinical experience, compared to Carmat's 108 implants and BiVACOR's six implants as of March 2025, highlighting SynCardia's superior track record.
• The SynCardia TAH replaces both left and right ventricles, allowing patient discharge, unlike LVADs and temporary MCS devices (e.g., Abbott HeartMate 3, Abiomed Impella, Getinge CardioHelp) which typically support only one ventricle and are for in-hospital use.
• Reimbursement for SynCardia TAH in the U.S. is under DRG 001, with payments ranging from $193,000 to $469,000, comparable to LVADs (DRG 001, $203,560 to $478,942) but significantly higher than ECMO ($170,000) or temporary axial flow devices ($90,000 and $40,000).
• SynCardia's 1-year post-transplant survival rates (80-86.6% in RWD studies) are strong indicators of clinical efficacy, although no prospective head-to-head trials exist against other TAHs or LVADs.
• Neurological event rates in SynCardia TAH RWD (5% of total adverse events) compare favorably to the PMA FDA study (27% for all implanted patients), suggesting improved real-world outcomes or reporting.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal matters or claims as of the date of the prospectus.
• Potential future litigation or claims may arise in the ordinary course of business, but are not anticipated to have a material adverse impact on financial position or cash flows, though they could be material to operating results for a particular period.
• The company maintains limited product liability insurance, which may not be sufficient to cover all claims.
• The company has agreed to indemnify the Selling Stockholders and certain other persons against certain liabilities in connection with the offering, including Securities Act liabilities.
• The institutional investor has agreed to indemnify the company against Securities Act liabilities arising from certain written information furnished by the Selling Stockholders.

Related Party Transactions

• On July 2, 2023, the company entered into a Capital Increase Agreement to invest $2.85 million for a 60% ownership interest in SynCardia Medical (Beijing), Inc., contingent on the company becoming publicly traded. Non-controlling owners would invest $2.85 million for 40%.
• On July 2, 2023, SynCardia Systems, LLC and SynCardia Medical (Beijing), Inc. entered an exclusive Distribution Agreement and a Regulatory Affairs Service Agreement.
• In 2024, the company sent approximately $540,000 worth of TAH product inventory to SynCardia Medical (Beijing), Inc. for regulatory registration inspection and testing, recorded as general and administrative expense.
• As of September 30, 2025, the company had a $137,000 balance receivable from Versa Capital Management, LLC (affiliated with Sindex, former owner of SynCardia) under an unsecured promissory note from September 27, 2021.
• Various interest-free and interest-bearing loans were extended by Hunniwell, Richard Fang (director), Fang Family Fund, LLC, and Fang Family Fund II, LLC (entities affiliated with executive directors) between June 2023 and June 2025, totaling several million dollars.
• Effective July 2, 2024, approximately $7.0 million in related party loans from Richard Fang and Fang Family Funds were consolidated into one convertible note (FFF Convertible Note) accruing 6% simple interest, convertible at a 50% discount to IPO price.
• On November 12, 2024, Richard Fang donated the $7.0 million aggregated convertible note and accrued interest to Nexus Science Foundation Inc. and Another Dimension Foundation (unrelated not-for-profit organizations).
• On September 2, 2025, the FFF Convertible Note (Nexus and Another Dimension notes) converted into 8,109,034 common shares due to the IPO.
• On September 3, 2025, several related party loans from Fang Family Fund II, LLC, totaling approximately $3.5 million in principal, plus accrued interest, were repaid.
• On September 4, 2025, a $580,000 loan from Fang Family Fund II, LLC plus $31,918 interest was repaid.
• On September 4, 2025, a $110,000 loan from Fang Family Fund II, LLC was repaid.
• On September 4, 2025, a $350,000 loan from Fang Family Fund II, LLC was repaid.
• On September 4, 2025, a $450,000 loan from Fang Family Fund II, LLC was repaid.
• On September 4, 2025, a $1.75 million loan from Fang Family Fund II, LLC plus $0.05 million interest was repaid.
• On September 9, 2025, a $250,000 related party working capital loan from Hunniwell plus $15,781 interest, a $93,633 Hunniwell travel expense reimbursement loan plus $5,237 interest, and a $187,190 Daniel Teo severance loan plus $2,042 interest were paid.
• On September 4, 2025, a $425,000 loan from Fang Family Fund I, LLC plus $4,533 interest was paid.
• On September 4, 2025, a $450,000 loan from Fang Family Fund I, LLC plus $1,200 interest was paid.
• As of September 30, 2025, the company determined it overpaid interest on Fang Family loans by $134,712, recognized as a receivable.
• On November 26, 2025, the company borrowed $1,000,000 from Fang Family Fund I, LLC at 6% interest, due November 27, 2026.
• On January 5, 2026, the $1,000,000 loan plus $6,575 interest, less the $134,712 related party receivable, was paid.
• The company has a written related person transaction policy for review and approval of transactions exceeding $120,000 or 1% of average total assets, involving officers, directors, 5% beneficial owners, or their immediate family members.

Stakeholder Impact

• **Shareholders:** Existing shareholders face significant dilution from the potential resale of 17,000,000 shares by Selling Stockholders, as well as from the conversion of convertible notes and exercise of warrants. The company's history of losses and 'going concern' warning indicate high investment risk. Future capital raises may further dilute ownership. The exclusive forum provision in the Charter may limit their ability to pursue litigation.
• **Selling Stockholders (HT Investments MA LLC and High Trail Special Situations LLC):** These institutional investors are offering up to 17,000,000 shares for resale, providing them with liquidity. They have significant influence through their senior secured notes and warrants, and participation rights in future financings.
• **Patients:** The company's focus on developing next-generation TAHs (Emperor) and upgraded drivers (Freedom+, Companion 3) aims to improve clinical outcomes, usability, and quality of life for patients with advanced heart failure. Expanded IFU for long-term use could offer more treatment options. However, product deficiencies like cannula tears, though not yet linked to SAEs, pose a safety concern.
• **Employees:** The company's ability to attract and retain highly qualified personnel is crucial for its future success, particularly in R&D, sales, and manufacturing. Stock-based compensation plans are in place to incentivize employees. The company considers its relationship with employees to be good.
• **Customers (Medical Centers/Hospitals):** The company's products are critical for heart transplant and MCS programs. Customer concentrations mean that changes in purchasing policies or economic difficulties of key customers could significantly impact the business. The company provides training and certification services to ensure proper use of its devices.
• **Suppliers:** The company relies on specialized third-party suppliers for critical components, with many being single-source. Disruptions or quality issues from these suppliers could severely impact manufacturing and product availability.
• **Creditors:** Holders of senior secured notes have a first-priority security interest in substantially all of the company's assets, placing their claims ahead of equity in a downside scenario. The company's 'going concern' status highlights repayment risks.

Next Steps

• Seek stockholder approval for the issuance of shares underlying the notes and warrants and an increase in authorized common stock at the next annual meeting.
• Continue nonclinical testing, including further animal studies and bench testing, for the Emperor Total Artificial Heart during the remainder of 2026 and 2027.
• Seek FDA approval for Emperor as early as 2028, depending on non-clinical activities and regulatory review outcomes.
• Receive FDA answer regarding the 180-day PMA supplement for expanded IFU (removing 'imminent death' and adding BTC) in the second quarter of 2026.
• Submit data to FDA to support long-term (2 years or more) use IFU, requiring at least 50 patients supported by SynCardia TAH for 24 months or more.
• Anticipate FDA approval for the upgraded portable Freedom+ Driver by the second half of 2025.
• Anticipate FDA approvals for next generation Freedom and C2 Drivers during the second halves of 2026 and 2027, respectively.
• Complete regulatory testing for the Unicorn driver system in the second half of 2026, with FDA submission as a 180-day PMA supplement expected to lead to approval by mid-2027.
• Complete process validation for the cannula tear design change and submit a 180-Day PMA Supplement to the FDA in approximately the third quarter of 2025.
• File submission for CE mark under MDR in Europe in the second half of 2025.
• Receive initial feedback on the NMPA application for SynCardia TAH in China during 2025, with expected approval within 12 months from filing.
• Initiate the process to bring SynCardia TAH to the Indian market, including filing for an MD-15 import license and seeking emergency use clearance.
• Train selected Indian transplant hospitals in the use of the SynCardia TAH and initiate importing and storing devices in Free Trade Zones (FTZs).
• Continue discussions with potential distribution partners in the Middle East, United Kingdom, Southeast Asia, Eastern and Central Europe, and Latin America.
• Hydrix Services Pty Ltd will provide engineering development services for Emperor through the end of 2026 as the initial phase of a multistage development program.

Key Dates

Recommendation

Picard Medical presents a high-risk, high-reward profile. The company holds a unique market position with the only FDA-approved total artificial heart for bridge to transplant, and its pipeline for next-generation devices like 'Emperor' is promising. The recent IPO and new secured financing provide a capital infusion, addressing immediate liquidity concerns. However, the persistent and increasing net losses, negative gross margins, and the auditor's 'going concern' warning signal significant operational and financial instability. The substantial dilution from the current resale offering and potential future capital raises, coupled with reliance on single-source suppliers and complex regulatory pathways, introduce considerable uncertainty. A 'hold' recommendation is appropriate for investors who are already exposed or are highly speculative, acknowledging the long-term potential of its innovative technology but recognizing the severe financial headwinds and execution risks that must be overcome to achieve sustained profitability.

Keywords

Total Artificial Heart, Medical Device, Heart Failure, Bridge to Transplant, FDA Approval, CE Mark, SynCardia TAH, Emperor TAH, Freedom Driver, Cardiovascular, Biotechnology, SEC Filing, S-1/A, Convertible Notes, Warrants, IPO, Regulatory Compliance, Intellectual Property, Supply Chain, Patient Outcomes, Healthcare Industry, Medical Technology